Clinical-stage biotechnology company K36 Therapeutics Inc on Thursday announced completion of dosing in the first patient cohort of its Phase 1 clinical trial evaluating KTX-2001, a first-in-class, orally administered, selective NSD2 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC).

This study marks the company's second NSD2 inhibitor to enter the clinic.

The Phase 1 clinical trial, STRIKE-001, is a multi-centre, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal androgen receptor inhibitor (Part B).

Terry Connolly, PhD, K36 Therapeutics' president and CEO, said: "KTX-2001 is a first-in-class NSD2 inhibitor targeting a long-recognised epigenetic driver of prostate cancer biology. Despite recent therapeutic advances, many patients ultimately exhaust effective options. This trial introduces a novel epigenetic mechanism with the potential to open an entirely new treatment paradigm for men with advanced disease."